OPTIMIZE
A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients With Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Arms / Cohorts
Experimental:Regimen A (MAC): Busulfan and Fludarabine, PBSC HCT; Reduce Dose PTCy
Accepting patients
Experimental:Regimen B (MAC): Fludarabine and TBI, PBSC HCT; Reduce Dose PTCy
Accepting patients
Experimental:Regimen C (RIC): Fludarabine and Busulfan; PBSCT HCT; Reduced Dose PTCy
Accepting patients
Experimental:Regimen D (RIC): Fludarabine and Melphalan; PBSCT HCT; Reduced Dose PTCy
Accepting patients
Experimental:Regimen E (NMA): Fludarabine, Cyclophosphamide, and TBI; PBSCT HCT; Reduced Dose PTCy
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.